Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-lactamase stability of faropenem.

A Dalhoff1, T Nasu, K Okamoto

  • 1Bayer AG Pharma Research Center, Wuppertal Germany. axel.dalhoff.ad@bayer-ag.de

Chemotherapy
|September 25, 2003
PubMed
Summary

Faropenem (FAR) demonstrates superior beta-lactamase stability and reduced resistance development compared to other cephalosporins and imipenem. This penem antibiotic offers enhanced efficacy against key bacterial pathogens like Staphylococcus aureus and Escherichia coli.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.

Antimicrobial agents and chemotherapy·2018
Same author

Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.

Antimicrobial agents and chemotherapy·2017
Same author

Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2015
Same author

Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2014
Same author

Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Infection·2012
Same author

A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Infection·2009

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Faropenem (FAR) is an orally available penem antibiotic.
  • Beta-lactamase (BLA) enzymes confer resistance to many beta-lactam antibiotics.
  • Understanding BLA stability and resistance emergence is crucial for antibiotic development.

Purpose of the Study:

  • To compare the beta-lactamase stability of faropenem (FAR) against other cephalosporins and imipenem.
  • To evaluate the propensity for resistance development in Staphylococcus aureus and Escherichia coli exposed to FAR.

Main Methods:

  • Beta-lactamase stability was assessed using enzyme preparations from various bacterial species.
  • Substrate hydrolysis was quantified spectrophotometrically.
  • Multistep acquisition of resistance was induced by serial passage in sub-inhibitory antibiotic concentrations.

Main Results:

  • Faropenem exhibited high stability against penicillinase and cephalosporinase from E. coli, P. vulgaris, and B. fragilis.
  • FAR was significantly more stable than cephaloridine, cefaclor, and cefotiam against certain cephalosporinases.
  • Resistance acquisition in S. aureus was less pronounced for FAR compared to cefixime, cefazolin, and cefaclor.

Conclusions:

  • Faropenem possesses superior beta-lactamase stability compared to other cephalosporins and imipenem.
  • FAR demonstrates a lower propensity for resistance development in Staphylococcus aureus.
  • These findings suggest faropenem's potential as an effective therapeutic agent against resistant bacteria.

Related Experiment Videos